CARDIOVASCULAR EFFECTS OF KRN2391, NITROGLYCERIN AND CROMAKALIM IN DIHYDROERGOTAMINE-TREATED PITHED RATS

被引:1
|
作者
KANETA, S
KASHIWABARA, T
TANAKA, Y
YOKOYAMA, T
IZUMI, H
IZAWA, T
OGAWA, N
机构
[1] Pharmaceutical Research Laboratory, KIRIN Brewery Co., Ltd., 3 Miyahara-cho, Takasaki, Gunma 370-12, Japan
来源
GENERAL PHARMACOLOGY | 1994年 / 25卷 / 05期
关键词
KRN2391; NITROGLYCERIN; CROMAKALIM; PITHED RAT; DIHYDROERGOTAMINE; CENTRAL VENOUS PRESSURE;
D O I
10.1016/0306-3623(94)90104-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The effects of KRN2391 on the cardiovascular system were compared with those of nitroglycerin and cromakalim in pithed rats treated with dihydroergotamine (DHE) in order to examine the effects of these drugs on venous blood vessels. 2. DHE (100 mu g/kg, i.v.) produced increases in mean blood pressure (MBP), cardiac output (CO) and central venous pressure (CVP) without changes in total peripheral vascular resistance (TPR) and heart rate (HR) based on venoconstriction. The DHE-treated pithed rats, nitroglycerin (30 mu g/kg, i.v.) decreased CO and CVP whereas cromakalim (30 mu g/kg, i.v.) produced a slight increase in CO followed by a decrease and did not affect CVP. KRN2391 (30 mu g/kg, i.v.) produced a decrease in CVP without affecting CO. Decreases in MBP and TPR were induced by all drugs. 3. These results suggest that nitroglycerin acts predominantly as a venodilator and KRN2391 and cromakalim showed a venodilating action in addition to an arterial dilating action in DHE treated pithed rats. However, the venodilating action of KRN2391 in this condition is more potent than that of cromakalim.
引用
收藏
页码:963 / 968
页数:6
相关论文
共 50 条
  • [21] Vasodilator effects of KRN2391, levcromakalim and 3-morpholino-sydnonimin in human pial and omental arteries
    Petersson, J
    Ryman, T
    Högestätt, ED
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 362 (01) : 68 - 73
  • [22] COMPARISON OF THE EFFECTS OF KRN2391 AND OTHER CORONARY DILATORS ON PORCINE ISOLATED CORONARY-ARTERIES OF DIFFERENT SIZES
    KASAI, H
    JINNO, Y
    KANETA, S
    FUKATA, Y
    FUKUSHIMA, H
    OGAWA, N
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1993, 45 (06) : 573 - 575
  • [23] Effects of KRN2391, a novel vasodilator acting as a nitrate and a K+ channel opener, on the rabbit lower urinary tract
    Waldeck, K
    Persson, K
    Andersson, KE
    GENERAL PHARMACOLOGY, 1995, 26 (07): : 1559 - 1564
  • [24] The effects of KRN2391 on circulation and renal sympathetic nerve activity in nerve-intact and baroreceptor-denervated rabbits
    Iwasawa, K
    Narita, H
    Unruh, GK
    Benson, K
    Goto, H
    ANESTHESIOLOGY, 2000, 93 (3A) : U173 - U173
  • [25] CARDIOVASCULAR EFFECTS OF ACETALDEHYDE IN PITHED RATS
    PAWLAK, D
    MALINOWSKA, B
    BUCZKO, W
    PHARMACOLOGY, 1992, 45 (02) : 83 - 89
  • [26] CARDIOVASCULAR EFFECTS OF COPPER IN PITHED RATS
    MACDONALD, E
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1984, 54 (01): : 76 - 80
  • [27] COMPARISON OF THE ANTI-VASOCONSTRICTOR EFFECTS OF A NOVEL VASODILATOR KRN2391, NICORANDIL AND NIFEDIPINE ON ISOLATED PORCINE LARGE CORONARY-ARTERY
    KASAI, H
    JINNO, Y
    KANETA, S
    TANAKA, Y
    FUKUSHIMA, H
    IZAWA, T
    OGAWA, N
    ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1993, 321 : 63 - 71
  • [28] PHARMACOLOGICAL ANALYSIS OF THE INHIBITORY EFFECTS OF KRN2391 ON ENDOTHELIN-1-INDUCED CONTRACTION IN ISOLATED LARGE CORONARY-ARTERY OF THE PIG
    HARADA, K
    MIWA, A
    YOKOYAMA, T
    IZAWA, T
    OGAWA, N
    JINNO, Y
    GENERAL PHARMACOLOGY, 1994, 25 (05): : 935 - 939
  • [29] IN-VITRO AND IN-VIVO K-CHANNEL-OPENING EFFECTS OF KI3315, A METABOLITE OF THE NOVEL VASODILATOR KRN2391
    TANAKA, Y
    OKADA, Y
    YOKOYAMA, T
    NAKAJIMA, T
    IZAWA, T
    FUKUSHIMA, H
    OGAWA, N
    ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1993, 326 : 62 - 71
  • [30] INOTROPIC AND CHRONOTROPIC EFFECTS OF KRN2391, A NOVEL VASODILATOR, ON ISOLATED GUINEA-PIG ATRIA (VOL 8, PG 23, 1993)
    JINNO, Y
    KANETA, S
    OHTA, H
    FUKUSHIMA, H
    IZAWA, T
    OGAWA, N
    ASIA PACIFIC JOURNAL OF PHARMACOLOGY, 1993, 8 (03): : 169 - 169